Does VEDOLIZUMAB Cause Tonsillar hypertrophy? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Tonsillar hypertrophy have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.0% of all adverse event reports for VEDOLIZUMAB.
9
Reports of Tonsillar hypertrophy with VEDOLIZUMAB
0.0%
of all VEDOLIZUMAB reports
0
Deaths
4
Hospitalizations
How Dangerous Is Tonsillar hypertrophy From VEDOLIZUMAB?
Of the 9 reports, 4 (44.4%) required hospitalization.
Is Tonsillar hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Tonsillar hypertrophy?
ADALIMUMAB (151)
ONDANSETRON (51)
SOMATROPIN (43)
SECUKINUMAB (42)
DUPILUMAB (39)
METHOTREXATE (39)
INFLIXIMAB (31)
TACROLIMUS (26)
INFLIXIMAB-DYYB (25)
ETANERCEPT (24)
Which VEDOLIZUMAB Alternatives Have Lower Tonsillar hypertrophy Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB